Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples

Background/Aim: To compare the GeneXpert® O6-methylguanine DNA methyltransferase (MGMT) methylation prototype (GX MGMT) assay with pyrosequencing in glioblastomas. Materials and Methods: The MGMT methylation status was retrospectively assessed in formalin-fixed paraffin embedded (FFPE) tumor blocks from 262 glioblastoma patients obtained from three independent cohorts using either a standard of care pyrosequencing laboratory developed test or the GX MGMT assay. Results: The concordance rate was 92.1% (58/63) for Oregon Health and Science University (OSHU) samples, 91.7% (88/96) for Medical University of Vienna (MUV) samples, and 82.5% (85/103) for Kepler University Hospital (KUH) samples. Patients with MGMT promoter hypermethylation assessed by pyrosequencing or the GX MGMT test had a significantly longer overall survival compared to patients without hypermethylation (HR=0.43, 95%CI=0.26-0.72, p=0.001 and HR=0.51, 95%CI=0.31-0.84, p=0.008, respectively). Conclusion: Standardized, simplified, and on-demand testing of MGMT promoter methylation by the GX MGMT assay is feasible.

[1]  K. Aldape,et al.  MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. , 2018, Neuro-oncology.

[2]  G. Reifenberger,et al.  European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.

[3]  M. Weller,et al.  Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. , 2015, Neuro-oncology.

[4]  C. Marosi,et al.  Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma , 2013, Clinical neuropathology.

[5]  G. Reifenberger,et al.  Predictive impact of MGMT promoter methylation in glioblastoma of the elderly , 2012, International journal of cancer.

[6]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[7]  M. Sanson,et al.  Comparative assessment of 5 methods (methylation‐specific polymerase chain reaction, methylight, pyrosequencing, methylation‐sensitive high‐resolution melting, and immunohistochemistry) to analyze O6‐methylguanine‐DNA‐methyltranferase in a series of 100 glioblastoma patients , 2012, Cancer.

[8]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[9]  M. Weller,et al.  Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma , 2012, PloS one.

[10]  R. Lothe,et al.  MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR , 2012, Journal of Translational Medicine.

[11]  G. Reifenberger,et al.  Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas , 2011, International journal of cancer.

[12]  Stephan Saikali,et al.  Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods , 2010, Journal of Neuro-Oncology.

[13]  J. Hainfellner,et al.  Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. , 2008, Clinical neuropathology.

[14]  J. Schramm,et al.  Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. , 2007, The Journal of molecular diagnostics : JMD.

[15]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.